| Literature DB >> 21453479 |
Trevor Clancy1, Marco Pedicini, Filippo Castiglione, Daniele Santoni, Vegard Nygaard, Timothy J Lavelle, Mikael Benson, Eivind Hovig.
Abstract
BACKGROUND: The immune contribution to cancer progression is complex and difficult to characterize. For example in tumors, immune gene expression is detected from the combination of normal, tumor and immune cells in the tumor microenvironment. Profiling the immune component of tumors may facilitate the characterization of the poorly understood roles immunity plays in cancer progression. However, the current approaches to analyze the immune component of a tumor rely on incomplete identification of immune factors.Entities:
Mesh:
Year: 2011 PMID: 21453479 PMCID: PMC3094196 DOI: 10.1186/1755-8794-4-28
Source DB: PubMed Journal: BMC Med Genomics ISSN: 1755-8794 Impact factor: 3.063
Figure 1Heterogeneous distribution of genes in immune databases and an incomplete catalogue of immune knowledge. (A) Bar chart depicting the shared gene distribution of the immune resources. 82 of the total integrated set of 4833 genes are common to all 6 manually curate resources (orange colored bar). Few genes were unique to an individual database, ranging from a minimum of two for "Immunome" and 122 for the "Innate". (B) An approximation using a Venn Euler diagram illustrates the heterogeneous overlap among the different databases. The Innate database being the largest resource has the largest intersections. The septic shock resource has smaller overlaps with the others (with the exception of Innate) highlighting its focus on collating genes related to the response to bacterial toxins during septic shock.
Figure 2Benchmarking of immunological relevance scores against manually curated immune resources. (A) The mean immune score for each database is depicted in the bar chart. The core immune genes are those 82 genes that are common to all immune resources and have a significantly larger amount of information content in comparison to each of the individual immune resources. (B) The frequency distribution of all HUGO name assigned genes reveals a sharp decline in immune relevance across the genome.
Figure 3The tumor-immunity interactome landscape. A three-dimensional surface plot representing the landscape of degree centrality (connectivity) of the interactome in the context of immune and cancer relevance: All axes are on the log scale and values above one on the log scale were considered high in terms of immune and cancer relevance. The consideration of one on the log scale as high in terms of immune relevance is made on the basis of the average immune scores for the expert sources ranging from 1 bit and above (see Figure 2). The color scale in the heatmap is representative of the connectivity of each gene in the human interactome. That which is apparent is the distinct areas of scattered high and low connectivity for genes in the cancer-immune landscape. The underlying data for this plot is detailed in Additional File 5.
Figure 4Immunological components of normal tissue. (A) Heatmap of the immunological gene expression fold-change comparisons among the 79 tissues from the SymAtlas [24]. This matrix displays the average immune score from those genes that contribute to greater than 2 times fold change difference between each tissue's pairwise comparisons. This combination of expression profiling and immunological grading detects a heterogeneous difference in the immunological components between tissues in a global manner. Both the X and Y-axis are numerical index of the 79 tissues (the mapping of this index to tissue name is listed in Additional File 8). With respect to the robustness of immune genes in the interactome : (B) Tissue specific interactome networks for Wholeblood (eccentricity centrality = 0.67) and Heart (eccentricity centrality = 0.72). The difference in the average eccentricity value is only marginally visible by eye as evidenced by a lower symmetry of the Heart network (the same transparent circle drawn on top of the two networks displayed by means of the same algorithm using the software yEd).
Figure 5Normalized frequency distribution of tissue specific eccentricity. The distribution (i.e., normalized frequency) of the gene eccentricity centralities for each of the tissue specific interactome networks (the same 79 human tissues profiled in Figure 4). Different network groups can be classified on the basis of the maximal value of the eccentricity distribution. Some network groups have a differential maximal value of distribution, and immune cells had the lowest values. The lower eccentricity values of immune cells reinforce the postulate that immune genes have robust reach throughout the human interactome. Equal colors in the legend correspond to equal maximal values of the normalized eccentricity.
Figure 6Comparison of the immunological component of skin cancer and states of melanoma progression. A heatmap of the average bits of immune information of the differentially expressed genes (> 2 times fold-change) among the pairwise comparisons of normal skin and skin cancer states. The labels from the left to right columns refer to normal skin tissues: ("Normal"), normal melanocyte ("Melanocyte") and then various states of skin cancer: primary melanoma ("Primary"), squamous cell carcinoma ("Squamous"), basal cell carcinoma ("Basal"), in-situ melanoma ("In Situ") and metastatic melanoma ("Metastatic"). Distinct differences in the immunological component of the various skin cancer and normal states are detected. We have focused here as an example, on the comparison between metastatic melanoma and normal human melanocytes. A subnetwork module from the interactome landscape of those genes with high immunological relevance is displayed. Upregulated genes are color-coded red and downregulated genes are color-coded green in this network. The size of a gene is proportional to the immunological relevance of the gene. There is clearly increased T-cell activity such as the presence of increased expression of CD8, CD4 and CD3 T-cell markers. This coincides with upregulation of key chemokine and cytokine interactions.
Top ranked immunological transitions of melanoma progression
| Gene comparison conditions | Highest graded immune genes | Significance to Melanoma progression |
|---|---|---|
| Upregulated (> 2fc) in both primary and metastatic melanoma compared to normal melanocyte (Immunological relevance score for each gene (KL) > 11 bits). | CD4, IL10, CD8A, CD40, IL15, IL7, IL18, TNFSF13B, PTPRC, IL13RA2, IL1A, PECAM1, C5AR1, CD86, ISG20, IL18R1, CD14, ITGB2, ADORA3, FCGR3A, CCL2, IL8, CCR5, FCGR3B | Signatures of T-cell infiltration, T-cell activation and the inflammatory response. Inclusive of the Th1 inhibiting cytokines |
| Downregulated (> 2fc) in both primary and metastatic melanoma compared to normal melanocyte (Immunological relevance score for each gene (KL) > 0.5 bits). | MME, IL24, DPP4, CYGB, MSC, SLC7A8 | Regulation of extracellular matrix (ECM) remodeling, through proteolytic enzymes, and amino acid transporters |
| Upregulated (> 2fc) in primary melanoma compared to normal melanocyte. Not subject to >2fc in metastasis (Immunological relevance score for each gene (KL) > 2 bits). | IL5, TNF, IL1RN, DARC, HLA-DRB4, CFP, PTPN6, CD1B, ELA2, IL17B, ATP8A2, SLPI, CD27, STAT4, CDA, IL26, DEFB4, NFKBIA, HRH1, XCL1, DEFB1, PDPN, CTSG, SDC1, GATA3, MSMB, CD24, POU1F1, PRDM1, EBF1 | Cytokine activity that is pro-survival and towards ECM remodeling. Increased transcriptional activity related to T-cell activation in the primary tumor. Increased presence of MHC class II markers. |
| Downregulated (> 2fc) in primary melanoma compared to normal melanocyte. Not subject to >2fc in metastasis (Immunological relevance score for each gene (KL) > 1 bit). | BAX, TNFRSF10B, SV2A | Down-regulation is indicative of p53 dysfunction and transduction of apoptosis signals. Overall leading to pro-survival in the primary tumor compared to normal cells |
| Upregulated (> 2fc) in metastatic melanoma compared to normal melanocyte. Not subject to >2fc in primary. (Immunological relevance score for each gene (KL) > 1 bit). | CCRL2, HLA-DRB1, MDK, C4A, CD55, CD80, FCGR1A, KLRC4, ICAM1, SPI1, HCST, PPBP, FCGR2C, GPR160, CXCL16, FOS, SERPINA1 | Mediators of inflammation, angiogenesis, cell growth, and cell migration. Also present are signals of humoral immunity in the form of T-cell activation and B-cell development genes |
| Downregulated (> 2fc) in metastatic melanoma compared to normal melanocyte. Not subject to >2fc in primary. (Immunological relevance score for each gene (KL) > 1 bit). | KIT, IRF4, MLANA, MMP1 | Down regulation of cell adhesion, differentiation factors and regulators of the innate and adaptive immune systems. Possibly promoting the metastatic phenotype |
| Upregulated (> 2fc) in metastatic melanoma compared to primary (Immunological relevance score for each gene (KL) < 1 bit). | MAGEA3, CSAG2, MAGEA2, GAGE1, MAGEA12, GAGE3, FKBP10 | Eliciting immune T cell activation in metastatic tumors, as a consequence of being expressed particularly in the metastatic stages, while having very restricted expression in normal cells |
| Downregulated (> 2fc) in metastatic melanoma compared to primary (Immunological relevance score for each gene (KL) > 1 bit). | S100A9, S100A8, SLPI, DEFB4, DEFB1, MSMB, CD24, DEFB103A, COL17A1 | Altered matrix remodeling and migratory behavior. Dynamic changes in the (ECM) in the metastatic tumors. Inclusive in this is the down regulation of important chemoattractants of innate immune cells |
Comparison of progressive melanoma states and their highest weighted immunological relevant genes